Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Comparative evaluation of cancer stem cell markers in normal pancreas and pancreatic ductal adenocarcinoma.

Vizio B, Mauri FA, Prati A, Trivedi P, Giacobino A, Novarino A, Satolli MA, Ciuffreda L, Camandona M, Gasparri G, Bellone G.

Oncol Rep. 2012 Jan;27(1):69-76. doi: 10.3892/or.2011.1461. Epub 2011 Sep 14.

2.

Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.

Jin A, Xu Y, Liu S, Jin T, Li Z, Jin H, Lin L, Lin Z.

Exp Mol Pathol. 2014 Feb;96(1):54-60. doi: 10.1016/j.yexmp.2013.11.003. Epub 2013 Nov 18.

PMID:
24263054
3.

Comparative proteomic analysis for the detection of biomarkers in pancreatic ductal adenocarcinomas.

Qi T, Han J, Cui Y, Zong M, Liu X, Zhu B.

J Clin Pathol. 2008 Jan;61(1):49-58. Epub 2007 Apr 5.

PMID:
17412869
4.

Clinicopathological correlations of nestin expression in surgically resectable pancreatic cancer including an analysis of perineural invasion.

Lenz J, Karasek P, Jarkovsky J, Muckova K, Dite P, Kala Z, Veselska R, Hermanova M.

J Gastrointestin Liver Dis. 2011 Dec;20(4):389-96.

5.

Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinomas.

Kure S, Matsuda Y, Hagio M, Ueda J, Naito Z, Ishiwata T.

Int J Oncol. 2012 Oct;41(4):1314-24. doi: 10.3892/ijo.2012.1565. Epub 2012 Jul 23.

PMID:
22824809
6.

Caveolin-1 overexpression correlates with tumour progression markers in pancreatic ductal adenocarcinoma.

Tanase CP, Dima S, Mihai M, Raducan E, Nicolescu MI, Albulescu L, Voiculescu B, Dumitrascu T, Cruceru LM, Leabu M, Popescu I, Hinescu ME.

J Mol Histol. 2009 Feb;40(1):23-9. doi: 10.1007/s10735-008-9209-7. Epub 2009 Jan 22.

PMID:
19160064
7.

Nestin and other putative cancer stem cell markers in pancreatic cancer.

Matsuda Y, Kure S, Ishiwata T.

Med Mol Morphol. 2012 Jun;45(2):59-65. doi: 10.1007/s00795-012-0571-x. Epub 2012 Jun 21. Review.

PMID:
22718289
8.

Actinin-4 expression in primary and metastasized pancreatic ductal adenocarcinoma.

Welsch T, Keleg S, Bergmann F, Bauer S, Hinz U, Schmidt J.

Pancreas. 2009 Nov;38(8):968-76. doi: 10.1097/MPA.0b013e3181b28d6f.

PMID:
19672209
9.

Claudin-4 expression predicts survival in pancreatic ductal adenocarcinoma.

Tsutsumi K, Sato N, Tanabe R, Mizumoto K, Morimatsu K, Kayashima T, Fujita H, Ohuchida K, Ohtsuka T, Takahata S, Nakamura M, Tanaka M.

Ann Surg Oncol. 2012 Jul;19 Suppl 3:S491-9. doi: 10.1245/s10434-011-1970-2. Epub 2011 Aug 12.

PMID:
21837532
10.

Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma.

Shekouh AR, Thompson CC, Prime W, Campbell F, Hamlett J, Herrington CS, Lemoine NR, Crnogorac-Jurcevic T, Buechler MW, Friess H, Neoptolemos JP, Pennington SR, Costello E.

Proteomics. 2003 Oct;3(10):1988-2001.

PMID:
14625861
11.
12.

Expression of the stem cell markers CD133 and nestin in pancreatic ductal adenocarcinoma and clinical relevance.

Kim HS, Yoo SY, Kim KT, Park JT, Kim HJ, Kim JC.

Int J Clin Exp Pathol. 2012;5(8):754-61. Epub 2012 Oct 1.

13.

Elevated L1CAM expression in precursor lesions and primary and metastastic tissues of pancreatic ductal adenocarcinoma.

Bergmann F, Wandschneider F, Sipos B, Moldenhauer G, Schniewind B, Welsch T, Schirrmacher P, Klöppel G, Altevogt P, Schäfer H, Sebens Müerköster S.

Oncol Rep. 2010 Oct;24(4):909-15.

PMID:
20811670
14.

Stem cell marker nestin is critical for TGF-β1-mediated tumor progression in pancreatic cancer.

Su HT, Weng CC, Hsiao PJ, Chen LH, Kuo TL, Chen YW, Kuo KK, Cheng KH.

Mol Cancer Res. 2013 Jul;11(7):768-79. doi: 10.1158/1541-7786.MCR-12-0511. Epub 2013 Apr 3.

15.

Low expression of IGFBP7 is associated with poor outcome of pancreatic ductal adenocarcinoma.

An W, Ben QW, Chen HT, Zheng JM, Huang L, Li GX, Li ZS.

Ann Surg Oncol. 2012 Nov;19(12):3971-8. doi: 10.1245/s10434-012-2407-2. Epub 2012 May 24.

PMID:
22622471
16.

Autophagy mediates survival of pancreatic tumour-initiating cells in a hypoxic microenvironment.

Rausch V, Liu L, Apel A, Rettig T, Gladkich J, Labsch S, Kallifatidis G, Kaczorowski A, Groth A, Gross W, Gebhard MM, Schemmer P, Werner J, Salnikov AV, Zentgraf H, Büchler MW, Herr I.

J Pathol. 2012 Jul;227(3):325-35. doi: 10.1002/path.3994. Epub 2012 Apr 18.

PMID:
22262369
17.

Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases.

Cao D, Zhang Q, Wu LS, Salaria SN, Winter JW, Hruban RH, Goggins MS, Abbruzzese JL, Maitra A, Ho L.

Mod Pathol. 2007 May;20(5):570-8. Epub 2007 Mar 30.

18.

Influence of interferon-α on the expression of the cancer stem cell markers in pancreatic carcinoma cells.

Zhu Y, Karakhanova S, Huang X, Deng SP, Werner J, Bazhin AV.

Exp Cell Res. 2014 Jun 10;324(2):146-56. doi: 10.1016/j.yexcr.2014.03.020. Epub 2014 Apr 13.

PMID:
24726912
19.

Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis.

Pham NA, Schwock J, Iakovlev V, Pond G, Hedley DW, Tsao MS.

BMC Cancer. 2008 Feb 6;8:43. doi: 10.1186/1471-2407-8-43.

20.

Differential cell cycle and proliferation marker expression in ductal pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia (PanIN).

Karamitopoulou E, Zlobec I, Tornillo L, Carafa V, Schaffner T, Brunner T, Borner M, Diamantis I, Zimmermann A, Terracciano L.

Pathology. 2010 Apr;42(3):229-34. doi: 10.3109/00313021003631379.

PMID:
20350215

Supplemental Content

Support Center